Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Their vision was clear, a bold, science-backed brand identity that communicates energy, confidence, and performance
At first glance, this profile appears incompatible with obesity therapy
It treats an effective treatment as something shameful, akin to how obesity is treated
Radovanic isn't alone
Regulatory Status: Retatrutide is an investigational compound in phase 3 clinical trials (as of June 29, 2025) and is not approved by the FDA or any other regulatory body for clinical use
US$ 26.59
US$ 22.01
US$ 21.45
